Argenx to Acquire Forte Biosciences in $2.2 Billion All-Cash Deal
Belgian-Dutch immunology company argenx has agreed to acquire U.S.-based Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion, marking a significant expansion of its autoimmune disease portfolio.
Under the terms of the agreement, argenx will pay $77 per share in cash for Forte Biosciences, giving the biotechnology company an equity value of around $2.2 billion. The acquisition is expected to strengthen argenx's research pipeline by adding FB102, an experimental therapy that has shown encouraging early clinical results in treating autoimmune diseases.
FB102 Strengthens Autoimmune Drug Portfolio
The centerpiece of the acquisition is FB102, a first-in-class anti-CD122 monoclonal antibody designed to target immune pathways linked to autoimmune disorders.
Early-stage studies suggest the therapy could have potential in treating conditions such as vitiligo, a chronic skin disorder that causes loss of pigmentation, and celiac disease, an autoimmune condition triggered by gluten consumption.
Although FB102 remains under clinical development, argenx believes the candidate complements its strategy of building a diversified portfolio focused on immune-mediated diseases.
Strategic Expansion for Argenx
The acquisition reflects argenx's continued investment in innovative therapies for patients with autoimmune conditions. The company has built a strong presence in immunology through the development of targeted antibody treatments and sees Forte Biosciences' research as an important addition to its long-term growth plans.
Industry analysts note that the transaction highlights continued merger and acquisition activity in the biotechnology sector, where companies are increasingly seeking promising late-stage and early-stage assets to strengthen future product pipelines.
Deal Highlights
The transaction is structured as a 100% cash acquisition, providing Forte Biosciences shareholders with immediate value while allowing argenx to gain full ownership of the company's lead experimental asset.
The companies expect the acquisition to accelerate the development of FB102 and broaden treatment options for patients with autoimmune diseases if future clinical trials prove successful and regulatory approvals are obtained.